Helix Biologics
Healthy100/100LargePharmaceutical
About this account
Top-20 pharma, global biologics portfolio, simultaneous FDA/EMA/PMDA programs.
Relationship health
100/100 · HealthyHow this account's health has moved over the last 5 weeks.
100 pts0 pts
4w ago2w agothis week
How touches have landed
Every logged touch with Helix Biologics, by outcome.
Meeting Booked1100%
Company profile
Qualified against your customer-type definitions — researched from the web, approved by you.
Customer type
Pharmaceutical - Large
Ownership
Public
Revenue
$8.2B
Applicable offerings (26)
Freya.RegisterRegulatory Information ManagementFreya.IntelligenceGlobal Regulatory IntelligenceFreya.GRR-PAC (Global Regulatory Requirements for Post Approval Changes)Global Regulatory IntelligenceFreya.LabelLabeling and ArtworkFreya.SubmitSubmissions and Document OperationsFreya.ArtworkLabeling and ArtworkFreya.RA ChangesRegulatory AffairsFreya.DocSubmissions and Document OperationsFreya.Register + Pia + MiaRegulatory Information ManagementFreya.GRR-PAC + ViaGlobal Regulatory IntelligenceFreya.Register + Pia + Mia + ViaRegulatory Information ManagementFreya.OmniObjectFreya Fusion Platform and AgentsPublishingSubmissions and Document OperationsSubmissions Planning & ManagementSubmissions and Document OperationsLabel ManagementLabeling and ArtworkArtwork ManagementLabeling and ArtworkRegulatory Affairs StrategyRegulatory AffairsRegulatory Affairs - Initial Applications & Market AccessRegulatory AffairsLocal Regulatory AffairsRegulatory AffairsPost-Approval Regulatory AffairsRegulatory AffairsRegulatory Intelligence ServicesGlobal Regulatory IntelligenceMedical Writing - ClinicalFreyr ServiceMedical Writing - Non Clinical & ToxicologyFreyr ServiceCompliance, Audit and ValidationFreyr ServiceMedical & Scientific CommunicationFreyr ServiceRIMS Data ServicesRegulatory Information Management
Agent briefing
Helix Biologics is in good shape — healthy, with $600K of open pipeline to grow. It's single-threaded, so widening the relationship would de-risk the deal. Recommended next move: Follow up with Helix Biologics.
HealthHealthy (100/100).
Pipeline1 open deal worth $600K.
ThreadingSingle-threaded on Dr. Lena Vogt — widen the relationship to de-risk.
MomentumLast touch Jul 19, 2026 • 7:03 PM.
Recommended: Follow up with Helix Biologics
Key Contacts
Value PropositionsAI generated
Global Labeling Strategy80% match
Position Global Labeling Strategy against Helix Biologics's near-term regulatory milestones.
Matched from your Freyr knowledge base
Regulatory Intelligence60% match
Single-pane monitoring across FDA, EMA and 120+ agencies.
Matched from your Freyr knowledge base
Angles to researchAI generated
Agent-suggested things worth checking before you reach out — verify before you rely on them.
Regulatory
Check for recent Pharmaceutical guidance that could tighten their submission timelines — a timely reason to reach out.
Hiring
See whether Helix is hiring in regulatory affairs — a growing team often means more submission workload they may need help with.